Immucell vs Rythm
Immucell is the larger business, with $27.6m of revenue in fiscal 2025 against $17.3m for Rythm (1.6 times as much). Rythm grew faster (95916.7% against 4.3%). Immucell kept more of each dollar of sales as profit: a net margin of -3.8% against -192.4%.
| Latest fiscal year | ImmucellICCC, 2025 | RythmRYM, 2025 |
|---|---|---|
| Revenue | $27.6m | $17.3m |
| Revenue growth | 4.3% | 95916.7% |
| Net income | −$1.0m | −$33.3m |
| Operating margin | 6.0% | — |
| Net margin | -3.8% | -192.4% |
| Return on equity | -3.8% | -161.8% |
| Free cash flow | $1.2m | −$23.5m |
| Cash | $3.8m | $32.2m |
| Total debt | $9.1m | $80.6m |
| Debt to equity | 33.6% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 73 | — |
| Market value | $95.8m | $35.5m |
| Price vs our value range | Above our value range | — |
| Moat score | 34 (Weak) | 17 (Weak) |
| Insider trades, 12 months | 8 buys, 0 sales | 0 buys, 11 sales |